Literature DB >> 19143025

VIP hypersecretion as primary or secondary syndrome in neuroblastoma: A retrospective study by the Société Française des Cancers de l'Enfant (SFCE).

Franck Bourdeaut1, Emilie de Carli, Sandra Timsit, Carole Coze, Pascal Chastagner, Sabine Sarnacki, Olivier Delattre, Michel Peuchmaur, Hervé Rubie, Jean Michon.   

Abstract

BACKGROUND: Neuroblastic tumors (NTs) are occasionally associated with watery diarrhea, due to Vasoactive Intestinal Peptide (VIP) secretion. Most reports are single cases and suggest a great homogeny within this sub-group of NTs. PROCEDURES: We conducted a retrospective analysis of the French experience of NTs associated with watery diarrhea due to VIP-secretion. VIP secretion was confirmed by seric dosage and/or immunohistochemistry.
RESULTS: Twenty-two patients met the diagnostic criteria between 1988 and 2007. Most of patients suffered from weight loss and metabolic disorders. In 16 cases, digestive symptoms preceded the diagnosis of the tumor ("Primary VIP secreting NTs"); 15 were localized and all showed a differentiated histology. Interestingly, in another 6 patients with high-risk NT, diarrhea occurred at the time of chemotherapy or retinoic acid therapy ("Secondary VIP secreting NTs"). Differentiation in response to treatment was documented in 4 cases. In all cases, only surgical excision of the tumor was able to control the digestive symptoms. Twenty children are alive and 13 are disease-free.
CONCLUSION: VIP secreting NTs are usually associated with differentiation; they can also secondarily arise from a high-risk tumor upon treatment. Primary surgery constitutes first-line treatment. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19143025     DOI: 10.1002/pbc.21912

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  9 in total

1.  Unremitting watery diarrhoea in early childhood period.

Authors:  Palittiya Sintusek; Thanita Thammarakcharoen; Shanop Shuangshoti; Boosba Vivatvakin
Journal:  BMJ Case Rep       Date:  2017-07-27

2.  Refractory diarrhea: A paraneoplastic syndrome of neuroblastoma.

Authors:  Wei Han; Huan-Min Wang
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

3.  Perinatal neuroblastoma of the pancreas.

Authors:  Simon Kargl; Bettina Frechinger; Wolfgang Pumberger
Journal:  Pediatr Surg Int       Date:  2012-09-25       Impact factor: 1.827

Review 4.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

5.  Neuroblastoma presenting with acute kidney injury, hyponatremic-hypertensive-like syndrome and nephrotic proteinuria in a 10-month-old child.

Authors:  Giovanni Maria Poggi; Giuliana Fognani; Daniela Cuzzubbo; Antonio Liguori; Massimo Resti; Ivana Pela
Journal:  Case Rep Oncol       Date:  2011-08-18

6.  Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastoma.

Authors:  Sanam Shahid; Brian H Kushner; Shakeel Modak; Ellen M Basu; Elyssa M Rubin; Gunes Gundem; Elli Papaemmanuil; Stephen S Roberts
Journal:  Pediatr Blood Cancer       Date:  2021-07-31       Impact factor: 3.838

7.  Neuroblastoma in early childhood: A rare case report and review of literature.

Authors:  Ritesh R Kalaskar; Ashita R Kalaskar
Journal:  Contemp Clin Dent       Date:  2016 Jul-Sep

8.  CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.

Authors:  Zhi-Yong Zhong; Bao-Jun Shi; Hui Zhou; Wen-Bo Wang
Journal:  J Int Med Res       Date:  2018-01-11       Impact factor: 1.671

9.  Uncommon reasons of the digestive tract-related paraneoplastic syndromes in children with neuroblastic tumors: three case reports.

Authors:  Elżbieta Czkwianianc; Beata Zalewska-Szewczyk; Józef Kobos; Anna Socha-Banasiak; Szymon Janczar; Sylwia Prymus-Kasińska; Joanna Kazanek-Zasada; Wojciech Młynarski
Journal:  Contemp Oncol (Pozn)       Date:  2018-04-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.